Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

  • Conferences
    • AACR19
    • AACR18
    • AACR17
    • AACR16
    • AACR15
    • AACR14
    • AACR IO
    • AAI ASGCT
    • ASCO GI
    • ASCO GU
    • ASCO-SITC
    • ASCO19
    • ASCO18
    • ASCO17
    • ASCO16
    • ASCO15
    • ASCO14
    • ASH18
    • ASH17
    • ASH16
    • ASH15
    • AUA
    • BMT
    • CIML40
    • CIMT
    • EACR
    • EAU
    • ECCO
    • ESMO18
    • ESMO17
    • ESMO16
    • ESMO14
    • JPM
    • Mol Targets
    • SABCS
    • SITC 2018
    • SITC 2017
    • SITC 2016
    • SITC 2015
    • SITC 2014
  • Targets
    • Bispecifics
    • Cytokines
    • MYC
    • Neoantigens
    • STING
  • About
  • Contact
  • Pricing
  • ESMO19
  • Premium Content
  • Immuno-Oncology
  • Cell Therapy
  • Interviews
  • Podcast
  • Login

  • ESMO19 Preview 2 – Targeting Synthetic Lethality and Immune Response in GU malignancies

    Read more

  • Controversies in triple negative breast cancer at ESMO19

    Read more

  • The many faces of lung cancer

    Read more

  • New developments in immunotherapy from WCLC19

    Read more

  • Targeting KRAS – Highlights from WCLC 2019

    Read more

  • Overcoming a hostile tumor microenvironment with Siglec-15

    Read more

  • Targeting Siglecs for Cancer Immunotherapy

    Read more
E

ESMO19 Preview 2 – Targeting Synthetic Lethality and Immune Response in GU malignancies

Preview of ESMO19 around targeting DNA damage repair (DDR) for GU cancers.

View post
E

Controversies in triple negative breast cancer at ESMO19

What should we be watching out for in terms of red and green flags at ESMO on the breast cancer IO front?

View post
E

The many faces of lung cancer

WCLC 2019 Review – Part 3 - Targeted Therapy Highlights excluding KRASi

View post

Terms of Use & Privacy Policy
Copyright © 2010-19 Biotech Strategy Blog

Sign Up for New Post Alerts
error: Content is protected !!